How biosimilar substitution rules work at the pharmacy and when a plan can require prior authorization

Biosimilar coverage turns on two different decisions. One is made at the pharmacy counter: substitution. The other is made by the health plan: utilization management. Related, yes. The same rule, no.

Pharmacy substitution is about what the pharmacist may dispense

A biosimilar is not automatically substituted just because it appears on a formulary. Substitution depends on whether the product meets the legal standard that lets a pharmacist replace the prescribed biologic without first getting a new prescription. If it does not, the pharmacist generally needs a prescription that names the biosimilar, or a prescriber-approved change, before dispensing it.

So a plan can financially prefer a biosimilar while the pharmacy still cannot switch to it on its own. That is where much of the confusion starts. A lower-cost coverage option does not always mean automatic substitution at the counter.

When prior authorization enters the picture, the issue is payment under plan rules

A plan can require prior authorization for a reference biologic, a biosimilar, or both. The process is fairly simple. Prior authorization requires the prescriber to submit clinical and administrative information before the claim is approved under the benefit. Plans use it to confirm that the requested product fits formulary rules, site-of-care rules, step requirements, or other benefit terms.

In practice, prior authorization often works as a steering tool. A plan may cover one biosimilar more easily than another product, or require extra documentation before covering a higher-cost option. That does not alter pharmacy substitution law. It affects payment approval.

Question What controls it What it affects
Can the pharmacist switch products without a new prescription? Substitution standard and state dispensing rules What can be dispensed at the counter
Will the insurer pay for the product under the benefit? Formulary placement, prior authorization, and other plan rules Coverage approval and member cost sharing

Before dispensing or filling, check both paths

Patients should ask two questions: Is the prescribed product eligible for pharmacy-level substitution under the applicable dispensing rules? And does the plan require prior authorization for the product that is actually being dispensed?

Pharmacists and benefits teams need to verify both the legal path and the coverage path. A clear substitution pathway does not guarantee paid coverage. And a preferred coverage pathway does not guarantee that the pharmacist can substitute independently.

For Medicare readers, Medicare.gov explains that some beneficiaries qualify for programs that lower Part D costs, including Extra Help for people with limited income and resources. That does not define a biosimilar rule on its own, but it still matters. Out-of-pocket exposure can shape whether a preferred product is realistically accessible.

Disclaimer: This article is for general educational purposes only and is not medical, legal, or insurance advice. Coverage, substitution authority, and prior authorization rules depend on the specific drug, prescriber order, state law, and health plan documents.

Sources